Instrument Inactif

Communiqués Nivalis Therapeutics Inc Nasdaq

Actions

US65481J1097

Recherche biotechnologique et médicale

Communiqués

09/05/24	Alpine Immune Sciences Reports First Quarter 2024 Financial Results	BU
26/04/24	ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN	BU
12/04/24	ALPINE IMMUNE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alpine Immune Sciences, Inc. - ALPN	BU
10/04/24	Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy	BU
10/04/24	Vertex Enters Into Agreement to Acquire Alpine Immune Sciences	BU
01/04/24	Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024	BU
21/03/24	Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024	BU
20/03/24	Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	BU
18/03/24	Alpine Immune Sciences : Corporate Presentation - March 2024	PU
18/03/24	Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results	BU
07/03/24	Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results	BU
26/02/24	Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences	BU
01/02/24	Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences	BU
21/12/23	Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie	BU
18/12/23	Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference	BU
20/11/23	Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference	BU
15/11/23	Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023	BU
14/11/23	Alpine Immune Sciences Reports Third Quarter 2023 Financial Results	BU
13/11/23	Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023	BU
07/11/23	Alpine Immune Sciences Announces Pricing of $150 Million Public Offering	BU
06/11/23	Alpine Immune Sciences : Results of Operations and Financial Condition - Form 8-K	PU
06/11/23	Alpine Immune Sciences Announces Proposed Public Offering	BU
03/11/23	Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting	BU
02/11/23	Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023	BU
30/10/23	Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023	BU